EGFR and lung adenocarcinoma: To the best of our knowledge, our study is the first to use PSM to compare the effects of EGFR-TKIs combined with craniocerebral radiotherapy and EGFR-TKIs alone on the prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastases.